Pterostilbene

Pterostilbene has dramatically superior pharmacokinetic properties compared to resveratrol. Pterostilbene's oral bioavailability is approximately 70-80% versus resveratrol's under 5%. Pterostilbene's plasma half-life is approximately 105 minutes versus resveratrol's 14 minutes. These pharmacokinetic advantages mean that pterostilbene at 50-150 mg achieves tissue concentrations comparable to resveratrol at 500-1500 mg or higher. The structural basis is the two methoxy groups at positions 3 and 5 on one of pterostilbene''s phenyl rings — these methoxy substitutions block glucuronidation (the primary metabolic pathway that destroys resveratrol in first-pass metabolism) and increase lipophilicity for better tissue distribution. Mechanistically, pterostilbene activates largely the same longevity-associated pathways as resveratrol (SIRT1, AMPK, Nrf2, NF-kB inhibition), with the added activity of PPAR-alpha agonism that resveratrol largely lacks. From a practical consumer standpoint: if the goal is SIRT1/AMPK activation and polyphenol-mediated longevity effects, pterostilbene delivers those outcomes at practical oral doses, whereas resveratrol requires extremely large doses to achieve comparable tissue exposure. McCormack 2012 (PMID 22082792) provides the human pharmacokinetic comparison.

The core human clinical evidence for pterostilbene comes from the Riche 2013 trial (PMID 23615358) at the University of Mississippi, which enrolled 80 adults with hypertension and dyslipidemia randomized to pterostilbene 50 mg twice daily, 125 mg twice daily, 50 mg twice daily plus grape extract, or placebo for 6-8 weeks. The high-dose pterostilbene group (250 mg/day) showed significant reductions in systolic blood pressure (approximately 7.8 mmHg) and diastolic blood pressure (approximately 7.3 mmHg). Lipid effects were mixed — HDL was modestly elevated in some groups, but LDL showed a slight increase in the high-dose group. Body weight was modestly reduced. McCormack 2012 (PMID 22082792) provided the pharmacokinetic data confirming 70-80% oral bioavailability in healthy volunteers. Riche 2014 (PMID 25048360) provided longer-term safety data confirming the LDL elevation signal at high doses. Smaller studies have examined cognitive, metabolic, and oxidative stress effects with generally favorable but preliminary results. The overall evidence grade is moderate — stronger than many novel supplements but weaker than well-established pharmaceuticals. Pterostilbene is best supported for mild blood pressure reduction in hypertensive adults at 100-250 mg daily, with supportive but less definitive evidence for other claims. Large long-term trials for cardiovascular events, diabetes prevention, or longevity outcomes do not exist.

The range most commonly used in clinical and commercial contexts is 50-150 mg daily, with 50 mg representing the entry dose (used in Elysium Health''s Basis formulation) and 100-150 mg representing the typical therapeutic dose. The Riche 2013 trial tested up to 125 mg twice daily (250 mg total per day) — the highest systematically studied dose. Above 250 mg daily, pterostilbene produces a modest increase in LDL cholesterol in a subset of users, as documented by Riche 2014 (PMID 25048360). The mechanism is believed to involve PPAR-alpha agonism affecting hepatic cholesterol metabolism. This LDL signal is dose-dependent and minimal at 100 mg daily, emerging at 250 mg daily. For users without cardiovascular disease or hyperlipidemia, occasional short-term use at 250 mg for specific blood pressure indications is reasonable with lipid monitoring. For long-term daily use, 50-150 mg is the safer range and captures most of the antioxidant, anti-inflammatory, and mitochondrial benefits without the lipid concern. Doses above 250 mg daily provide no documented additional clinical benefit and should not be pursued.

Elysium Health''s Basis combines pterostilbene 50 mg + nicotinamide riboside 250 mg in a single capsule-based daily supplement priced at approximately $60-80 per month. The combination is mechanistically coherent: NR provides NAD+ substrate for sirtuin enzymes, and pterostilbene activates those enzymes allosterically. Clinical studies sponsored by Elysium have confirmed safe NAD+ elevation in healthy adults. From a pricing standpoint, the combination is generally more expensive than purchasing pterostilbene 50 mg and NR 250 mg as separate standalone products (which together can be obtained for $30-50 per month from generic brands). Users should weigh: (1) convenience of combined capsule versus separate products, (2) brand reputation and quality assurance provided by Elysium (including clinical trial investment and ingredient verification), (3) alternative formulations that may offer better value (e.g., ChromaDex-branded Tru Niagen for NR + standalone pTeroPure for pterostilbene). For users new to longevity supplementation who want a simplified single-product approach from a reputable brand, Basis is reasonable. For users willing to buy individual components, equivalent doses can be achieved at substantially lower cost with minimal quality compromise if generic brands from reputable manufacturers are selected. The clinical evidence supports the combination at roughly the same grade as either component individually.

Yes, based on the Riche 2013 trial (PMID 23615358), pterostilbene at 125 mg twice daily (250 mg total per day) produces statistically and clinically significant reductions in blood pressure in hypertensive adults. The observed effect was approximately 7.8 mmHg systolic and 7.3 mmHg diastolic at 6-8 weeks. This is a meaningful reduction — comparable in magnitude to the effect of many first-line antihypertensive medications — though pterostilbene is not FDA-approved as an antihypertensive and should not replace prescribed medications in patients with established hypertension. The mechanism involves improved endothelial function (enhanced nitric oxide bioavailability through eNOS upregulation), modest diuretic-like effects, and anti-inflammatory vascular effects. Practical use: for users with mild hypertension (e.g., systolic 130-145 mmHg) not yet on antihypertensive medication, pterostilbene 100-200 mg daily is a reasonable adjunct to lifestyle modification. Users on existing antihypertensive medications should monitor for hypotension when initiating pterostilbene. Users with uncontrolled severe hypertension should pursue standard medical management first; pterostilbene alone is insufficient. Effect takes 4-8 weeks to develop fully and requires continuous use to maintain.

The landscape of purported SIRT1 activators includes resveratrol, pterostilbene, SRT1720 and SRT2104 (synthetic compounds developed by Sirtris, now discontinued), and various naturally-occurring polyphenols with indirect effects. Pterostilbene has the best combination of oral bioavailability, human safety data, and confirmed SIRT1 activation among readily available SIRT1 activators. Compared to resveratrol: pterostilbene has dramatically better pharmacokinetics as described above. Compared to SRT1720 and SRT2104: these synthetic compounds showed promising preclinical SIRT1 activation but were discontinued in clinical development; their absolute SIRT1 selectivity and potency exceeded pterostilbene, but they are not commercially available. Compared to other polyphenol indirect SIRT1 activators (quercetin, fisetin, curcumin, EGCG): these compounds have additional mechanisms beyond SIRT1 and overlapping longevity-associated activities; pterostilbene remains the most specifically-branded and most-studied direct SIRT1 activator among naturally-derived oral supplements. For users whose primary goal is SIRT1 activation with confirmed oral bioavailability and human safety data, pterostilbene is the current best choice. Combining pterostilbene with other polyphenols (quercetin, fisetin) for broader pathway coverage is a reasonable stacking approach.

Pterostilbene has an excellent safety profile, with the main clinically-relevant concerns being relatively modest: (1) LDL cholesterol elevation at doses of 250 mg daily or above, as documented in Riche 2014 — this is the primary dose-limiting toxicity and is minimal at 100 mg daily or below; (2) additive blood pressure reduction when combined with antihypertensive medications — can produce symptomatic hypotension, particularly postural, and requires monitoring when initiating in patients on existing blood pressure-lowering medications; (3) mild antiplatelet effects that may theoretically enhance bleeding tendency with anticoagulants — clinical significance likely modest at typical supplementation doses but warrants discontinuation 7-10 days before surgical procedures; (4) gastrointestinal discomfort (nausea, bloating, stomach upset) in 5-10% of users, particularly when taken on empty stomach — typically resolves with food co-administration; (5) headaches in a minority of users, usually transient; (6) theoretical hormone-receptor modulation of uncertain clinical significance — caution in estrogen-dependent cancer history. Pterostilbene is not recommended during pregnancy, lactation, or in children due to absence of safety data in these populations. Long-term safety data beyond 1-2 years are less extensive but the Basis product has been marketed since 2014 with no major emerging safety signals. Users with cardiovascular disease, hyperlipidemia, or on antihypertensive or anticoagulant medications should consult physicians before use.

Dietary blueberries contain measurable pterostilbene (99-520 ng per gram, approximately 15-100 mcg per cup) and regular blueberry consumption delivers some pterostilbene exposure. However, the doses associated with clinical benefits in the Riche 2013 trial (100-250 mg daily) are far beyond what can realistically be obtained from blueberry consumption — you would need to eat hundreds to thousands of cups of blueberries daily to reach those doses. For reference, a typical serving of 1/2 cup of blueberries provides perhaps 7-50 mcg of pterostilbene, which is 2000-14000 times less than a 100 mg supplement dose. That said, blueberry consumption is independently beneficial for multiple reasons beyond pterostilbene: anthocyanins, other flavonoids, fiber, vitamin C, and other polyphenols collectively contribute to documented cardiovascular and cognitive benefits observed in blueberry-rich diets. Users who eat berries regularly are benefiting from polyphenol exposure broadly; users who specifically want the clinically-tested pterostilbene dose for blood pressure or SIRT1 activation should supplement in addition to dietary sources. A reasonable integrated approach is: daily blueberries or other berries as part of a Mediterranean-style diet, plus supplemental pterostilbene 50-100 mg daily for the specific pterostilbene-mediated effects.

Both combinations have theoretical rationale and are pursued by some users in longevity medicine contexts, though neither has been rigorously tested in randomized clinical trials for combined efficacy or safety. Pterostilbene + metformin: both activate AMPK through distinct mechanisms (pterostilbene indirectly through SIRT1 crosstalk; metformin primarily through mitochondrial complex I inhibition and downstream AMP elevation). The combination may produce additive AMPK-mediated effects on insulin sensitivity, hepatic lipogenesis, and autophagy. Practical considerations: metformin is prescription-only in the US, requiring physician oversight; the combination can produce hypoglycemia in diabetic patients on insulin or sulfonylureas; gastrointestinal effects of metformin may be additive with pterostilbene''s mild GI effects. Typical dosing in longevity protocols: metformin 500 mg twice daily + pterostilbene 50-100 mg daily. Pterostilbene + rapamycin: rapamycin inhibits mTOR complex 1, while pterostilbene activates AMPK (which indirectly inhibits mTOR); theoretically complementary. Rapamycin is a pharmacologically potent immunosuppressant with significant side effects including mouth ulcers, lipid elevations, infection risk, and metabolic disturbances — it is not a casual supplement. Combining pterostilbene with rapamycin requires physician supervision and is not recommended for general use. Pterostilbene''s LDL elevation signal at high doses combines unfavorably with rapamycin''s lipid elevation; lower pterostilbene doses (50 mg daily) are preferred in rapamycin contexts. Overall: both combinations are reasonable for experienced users with physician oversight but are not established first-line approaches for general longevity supplementation.

Pterostilbene''s effects develop on different timescales depending on the measured outcome. Pharmacokinetic effects — measurable plasma levels — are immediate, with peak concentrations within 1-2 hours of a dose. Biomarker effects — reductions in oxidative stress markers, inflammatory markers, and modest changes in antioxidant enzyme activity — develop over 4-8 weeks of consistent daily supplementation. Blood pressure effects in hypertensive adults, as measured in the Riche 2013 trial, are significant at 6-8 weeks of continuous use. Metabolic effects (lipid profile changes, insulin sensitivity) are slower — typically requiring 8-12 weeks or longer of consistent use to manifest. Longevity-oriented effects on aging biomarkers, biological age clocks, and clinical outcomes require months to years of continuous supplementation and cannot be assessed over short intervals. Discontinuation: pterostilbene''s effects are reversible with discontinuation — blood pressure effects return to baseline within 1-2 weeks, biomarker effects within 4-8 weeks. There is no withdrawal syndrome or rebound phenomenon with abrupt discontinuation. Users can start, stop, and restart pterostilbene without special tapering. Practical implication: pterostilbene is most appropriately conceptualized as a long-term daily supplement rather than a short-term intervention. Users should plan to take it continuously for months or years to accrue meaningful benefits, reassessing periodically with their physician based on individual response, evolving clinical research, and personal goals.